Stanford University
Showing 1,381-1,390 of 2,401 Results
-
Timothy Meyer
Stanford University Professor of Nephrology, Emeritus
Current Research and Scholarly InterestsInadequate removal of uremic solutes contributes to widespread illness in the more than 500,000 Americans maintained on dialysis. But we know remarkably little about these solutes. Dr. Meyer's research efforts are focused on identifying which uremic solutes are toxic, how these solutes are made, and how their production could be decreased or their removal could be increased. We should be able to improve treatment if we knew more about what we are trying to remove.
-
Lekha Mikkilineni
Assistant Professor of Medicine (Blood and Marrow Transplantation & Cellular Therapy)
BioDr. Lekha Mikkilineni is a board-certified medical oncologist. She is also an Assistant Professor in the Department of Medicine, Division of Blood & Marrow Transplant and Cellular Therapy.
Dr. Mikkilineni has extensive experience treating blood and bone marrow cancers. She currently provides care through the Bone Marrow Transplant & Cellular Therapy Program at Stanford Health Care. Her clinical focus is multiple myeloma, plasma-cell leukemia, Extramedullary myeloma, high-risk myeloma, CAR T cell therapy, bispecific therapy, amyloidosis, POEMS syndrome, and Waldenstrom’s macroglobunemia.
Dr. Mikkilineni’s research centers on exploring novel CAR T-cell therapies to treat multiple myeloma and to define mechanisms of resistance to immunotherapy. She is particularly focused on understanding how to improve therapies for multiple myeloma patients who have extramedullary disease or high-risk features. Prior to coming to Stanford, she ran phase 1 CAR T-cell trials for multiple myeloma targeting BCMA and SLAMF7 at the National Cancer Institute.
Dr. Mikkilineni received the Conquer Cancer Foundation Young Investigator Award from the American Society of Clinical Oncology for her research focusing on SLAMF7 as a potential target for multiple myeloma. She has received honors and awards for her work at the NCI. She has completed fellowships in hematology/oncology and immunotherapy at the National Heart, Lung, and Blood Institute/National Cancer Institute. She finished her residency in internal medicine at Thomas Jefferson University Hospital. She holds a Master of Science in medical sciences from Boston University and a medical degree from Tulane University.
Dr. Mikkilineni has authored book chapters and published research in numerous high-impact academic journals. She has presented her findings through oral and poster presentations at national and international conferences. -
David Miklos
James and Katherine Lau Professor
Current Research and Scholarly InterestsDr. Miklos is the Chief of BMT & Cell Therapy Program. He leads clinical trials treating patients with lymphoma. His correlative research studies: 1) tumor antigen quantification, 2) single cell functional product characterization, 3) CAR-FACS immune phenotyping of blood and tumor, and identifying mechanisms for CAR-T treatment Failure including antigen loss, CAR-T exhaustion, and CAR suppression.
-
Christina Milcarek
Executive Administrator, Med/Stanford Center for Clinical Research
Current Role at StanfordProviding executive support to:
Dr. Kenneth Mahaffey, Founding Director, Stanford Center for Clinical Research (SCCR) -
Carlos Milla
Professor of Pediatrics (Pulmonary Medicine) and, by courtesy, of Medicine (Pulmonary, Allergy and Critical Care Medicine)
Current Research and Scholarly InterestsAt Stanford University I developed and currently direct the CF Translational Research Center. The overarching goal of the center is to provide the groundwork to streamline, accelerate, and promote the translation of basic discoveries into effective therapies and interventions to benefit patients affected by cystic fibrosis. My laboratory group currently has three main lines of investigation: respiratory cell biology in CF; remote biochemical monitoring; and lung physiology in young children.
